

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNS THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Biosante Pharmaceuticals, Inc.		04/13/2011	CORPORATION: DELAWARE
RECEIVING PARTY DATA			
Name:	Takeda Pharmaceutical Company Limited		
Street Address:	1-1, Doshomachi 4-chome, Chuo-ku		
City:	Osaka 540-8645		
State/Country:	JAPAN		
Entity Type:	CORPORATION: JAPAN		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Registration Number:	2780479	CHANGING THE FUTURE OF ONCOLOGY	
CORRESPONDENCE DATA			
Fax Number:	2024084400		
	<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	202 408-4073		
Email:	docketing@finnegan.com		
Correspondent Name:	B. Brett Heavner		
Address Line 1:	901 New York Avenue, NW		
Address Line 4:	Washington, DISTRICT OF COLUMBIA 20001-4413		
ATTORNEY DOCKET NUMBER:	04221.1367		
DOMESTIC REPRESENTATIVE			
Name:	B. Brett Heavner of Finnegan, et al.		
Address Line 1:	901 New York Avenue, NW		
Address Line 4:	Washington, DISTRICT OF COLUMBIA 20001-4413		

OP \$40.00 2780479

NAME OF SUBMITTER:	B. Brett Heavner
Signature:	/b. brett heavner/
Date:	06/01/2012
Total Attachments: 2 source=assignment1#page1.tif source=assignment1#page2.tif	

EXHIBIT A

ASSIGNMENT OF TRADEMARK

United States

THIS ASSIGNMENT OF TRADEMARK is made by Cell Genesys, Inc., through its successor-in-interest, BioSante Pharmaceuticals, Inc., a Delaware corporation with an address at 111 Barclay Boulevard, Lincolnshire, Illinois 60069 ("Cell Genesys"), in favor of Takeda Pharmaceutical Company Limited, a Japanese company with an address at 1-1, Doshomachi 4-chome, Chuo-ku, Osaka 540-8645 ("Takeda Pharmaceutical").

WHEREAS, Cell Genesys owns all right, title and interest in and to the trademark and the registration thereof identified in the attached Schedule A (the "Mark"), and the goodwill associated therewith;

WHEREAS, Cell Genesys desires to assign the Mark to Takeda Pharmaceutical and Takeda Pharmaceutical desires to acquire the Mark.

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, Cell Genesys assigns to Takeda Pharmaceutical all of its right, title and interest in the Mark together with the goodwill associated therewith including, without limitation, its right to sue for and collect damages for infringement or other violations of the same, including for past infringements or other violations.

IN WITNESS WHEREOF, this Assignment of Trademark has been duly executed and effective as of the date set forth below:

CELL GENESYS, INC.

By: BIOSANTE PHARMACEUTICALS, INC.
Its Successor-in-Interest

By: Philip B. Dornberg
Name: PHILIP B. DORNBERG
Title: SVP Finance, CFO
Date: 4/13/11

SCHEDULE A

Mark	App. No. Filing Date	Reg. No. Reg. Date	Class
CHANGING THE FUTURE OF ONCOLOGY	76/401,235 04/26/2002	2,780,479 11/04/2003	42

OHS West.261093182.1
23561-6600 R04/RP1